Godkännande av Bosulif

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study 
Hochaus et al, Leukemia, 2020 Aug;34(8):2125-2137 
https://pubmed.ncbi.nlm.nih.gov/32572189/ 

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia 
Brümmendorf et al Ann Hematol, 2020 Jun;99(6):1241-1249 
https://pubmed.ncbi.nlm.nih.gov/32307568/ 

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial 
Gambacorti-Passerini et al, Blood, Volume 138, Supplement 1, 23 November 2021, Page1475
https://ashpublications.org/blood/article/138/Supplement%201/1475/480608/Efficacy-and-Safety-of-Bosutinib-in-Previously

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib 
Cortes JE, et al, Blood. 2011 Oct 27; 118(17): 4567–4576 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916618/ 

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure 
Khoury HJ, et al, Blood, 2012 Apr 12;119(15):3403-12 
https://pubmed.ncbi.nlm.nih.gov/22371878/ 

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial 
Cortes JE, et al, J Clin Oncol, 2018 Jan 20;36(3):231-237 
https://pubmed.ncbi.nlm.nih.gov/29091516 

Relaterade behandlingsområden

PP-BOS-SWE-0144, mar 2022